Scleroderma (Systematic Sclerosis) is undoubtedly one of the most challenging rheumatic diseases to treat. Lung involvement is a major determinant of morbidity and mortality.
This study demonstrates equivalent efficacy of Mycophenolate to Cyclophosphamide in improving both lung function and skin scores in patients with Scleroderma. Unlike Cyclophosphamide, Mycophenolate does not cause subfertility or increased future malignancy risk. But it comes at a much higher cost.
www.rheumatologynews.com|By Rheumatology News
It is often said that, "No drug is totally useless until it has been tried in Scleroderma." It is no wonder that any successful drug trial in SSc is met with skeptical enthusiasm.
Will Pirfenidone benefit rheumatic patients with inflammatory lung disease?